BACKGROUND: Oxidative stress has been implicated in inflammatory demyelination. The glutathione S-transferase (GST) supergene family encodes isoenzymes that appear to be critical in protection against oxidative stress. Certain GST loci are polymorphic, demonstrating alleles that are null (GSTM1/GSTT1), encode low activity variants (GSTP1), or are associated with variable inducibility (GSTM3). OBJECTIVES: To investigate the association between clinical outcome in MS and allelic variants of GSTM1, GSTM3, GSTT1, and GSTP1. METHODS: Four hundred patients with clinically definite MS were studied. Disability was measured using the Kurtzke Expanded Disability Status Scale (EDSS). Disability was graded as mild (EDSS 0-4), moderate (4.5-5.5), or severe (EDSS 6-10). PCR-based genotyping was performed using DNA extracted from lymphocytes. Significant associations between GST genotypes and clinical outcome were corrected for gender, onset age, and disease duration using logistic regression. RESULTS: We found that the GSTM3 AA genotype was associated with severe disability in patients with a disease duration of more than 10 years (p = 0.027, n = 177, OR = 2.4, 95% CI = 1.1-5.0). Homozygosity for both GSTM1*0 and GSTP1*Ile105 containing allele was associated with severe disability in patients with a disease duration greater than 10 years (p = 0.022, n = 179, OR = 5.0, 95% CI = 1.3-19.8). CONCLUSIONS: Our results suggest that long-term prognosis in MS is influenced by a genetically determined ability to remove the toxic products of oxidative stress.
BACKGROUND: Oxidative stress has been implicated in inflammatory demyelination. The glutathione S-transferase (GST) supergene family encodes isoenzymes that appear to be critical in protection against oxidative stress. Certain GST loci are polymorphic, demonstrating alleles that are null (GSTM1/GSTT1), encode low activity variants (GSTP1), or are associated with variable inducibility (GSTM3). OBJECTIVES: To investigate the association between clinical outcome in MS and allelic variants of GSTM1, GSTM3, GSTT1, and GSTP1. METHODS: Four hundred patients with clinically definite MS were studied. Disability was measured using the Kurtzke Expanded Disability Status Scale (EDSS). Disability was graded as mild (EDSS 0-4), moderate (4.5-5.5), or severe (EDSS 6-10). PCR-based genotyping was performed using DNA extracted from lymphocytes. Significant associations between GST genotypes and clinical outcome were corrected for gender, onset age, and disease duration using logistic regression. RESULTS: We found that the GSTM3 AA genotype was associated with severe disability in patients with a disease duration of more than 10 years (p = 0.027, n = 177, OR = 2.4, 95% CI = 1.1-5.0). Homozygosity for both GSTM1*0 and GSTP1*Ile105 containing allele was associated with severe disability in patients with a disease duration greater than 10 years (p = 0.022, n = 179, OR = 5.0, 95% CI = 1.3-19.8). CONCLUSIONS: Our results suggest that long-term prognosis in MS is influenced by a genetically determined ability to remove the toxic products of oxidative stress.
Authors: Hetty Prinsen; Robin A de Graaf; Graeme F Mason; Daniel Pelletier; Christoph Juchem Journal: J Magn Reson Imaging Date: 2016-06-28 Impact factor: 4.813
Authors: José A G Agúndez; Elena García-Martín; Carmen Martínez; Julián Benito-León; Jorge Millán-Pascual; María Díaz-Sánchez; Patricia Calleja; Diana Pisa; Laura Turpín-Fenoll; Hortensia Alonso-Navarro; Lucía Ayuso-Peralta; Dolores Torrecillas; Esteban García-Albea; José Francisco Plaza-Nieto; Félix Javier Jiménez-Jiménez Journal: Cell Mol Immunol Date: 2014-12-22 Impact factor: 11.530
Authors: Ted R Mikuls; Tricia Levan; Karen A Gould; Fang Yu; Geoffrey M Thiele; Kimberly K Bynote; Doyt Conn; Beth L Jonas; Leigh F Callahan; Edwin Smith; Richard Brasington; Larry W Moreland; Richard Reynolds; Angelo Gaffo; S Louis Bridges Journal: Arthritis Rheum Date: 2012-03
Authors: Christina J Azevedo; John Kornak; Philip Chu; Mehul Sampat; Darin T Okuda; Bruce A Cree; Sarah J Nelson; Stephen L Hauser; Daniel Pelletier Journal: Ann Neurol Date: 2014-07-09 Impact factor: 10.422
Authors: Mehdi Aliomrani; Mohammad A Sahraian; Hamid Shirkhanloo; Mohammad Sharifzadeh; Mohammad R Khoshayand; Mohammad H Ghahremani Journal: Neurol Sci Date: 2017-04-21 Impact factor: 3.307
Authors: Carrie V Breton; Hita Vora; Muhammad T Salam; Talat Islam; Made Wenten; W James Gauderman; David Van den Berg; Kiros Berhane; John M Peters; Frank D Gilliland Journal: Am J Respir Crit Care Med Date: 2009-01-16 Impact factor: 21.405